Back to CVE records
Low 2.2Published Aug 4, 2026

CVE-2026-18817A security flaw has been discovered in Baserow up to 2.3.2.

Updated under an hour ago ()

Does this affect you?

It lists no affected products yet. Add what you run and Signals checks it as products are added.

No exploitation reported and no EPSS estimate yet.

A security flaw has been discovered in Baserow up to 2.3.2. Affected by this issue is the function BaserowImpersonateAuthTokenSerializer of the file backend/src/baserow/api/admin/users/serializers.py of the component Inactive Non-Staff User Handler. Performing a manipulation results in improper authorization. Remote exploitation of the attack is possible. The complexity of an attack is rather high. The exploitation is known to be difficult. The presence of this vulnerability remains uncertain at this time. Upgrading to version 2.3.3 can resolve this issue. The affected component should be upgraded. The project maintainer explains: "While the problem exists, I'm not really sure if it's a vulnerability. (....) Even though the back gives a token for a deactivate user, none of the endpoints actually work. That said, we will fix it, but so far it seems more like a bug instead of a vulnerability."

CVSS
2.2 LOW (v3.1, NVD)CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:U/C:N/I:L/A:N
Weakness (CWE)
CWE-266, CWE-285
Known exploited
Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days)
Not loaded for this CVE
Assigned by
Not given
NVD analysis
Deferred
Record last updated
Aug 12, 2026
First seen by InfoSec Signals
Oct 9, 2026

Affected products

No affected products are listed yet.

References

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.

Your cookie choices
We use essential cookies to run this site, and, only with your consent, an advertising cookie from Google to measure whether our ads lead to sign-ups and subscriptions. See our for details.